Acceder
  1. Inicio
  2. Perfil de Moneyintruder
  3. Contenidos recomendados por Moneyintruder

Contenidos recomendados por Moneyintruder

Moneyintruder 22/12/17 16:24
Ha respondido al tema Chicharros USA - bolsa internacional
FELIZ NAVIDAD Sube en el after!!! FAMILIA RANKIA CHICHARROS USA Salta, salta!!! Un placer 'conoceros', creo aprender de cara a un mejor futuro...Gracias a todos por vuestras aportaciones. Ya si encima hacemos negocio mejor ;-) Un abrazote y felices fiestas
Ir a respuesta
Moneyintruder 22/12/17 07:08
Ha respondido al tema Chicharros USA - bolsa internacional
RXDX Esta si que es buena... RXDX es Ignyta En premarket 72% ahora Roche to buy U.S. cancer drugmaker Ignyta for $1.7 bln Reuters ReutersDecember 22, 2017 Logo of Swiss drugmaker Roche is seen beside the entrance of its research unit Roche Glycart AG in Schlieren, Switzerland December 18, 2017. REUTERS/Arnd Wiegmann Logo of Swiss drugmaker Roche is seen beside the entrance of its research unit Roche Glycart AG in Schlieren Logo of Swiss drugmaker Roche is seen beside the entrance of its research unit Roche Glycart AG in Schlieren, Switzerland December 18, 2017. REUTERS/Arnd Wiegmann More (Reuters) - Swiss drugmaker Roche will buy U.S. cancer drug specialist Ignyta Inc for $1.7 billion in an agreed deal to broaden its oncology portfolio, the firms said on Friday. Roche would pay $27 per share for Ignyta, representing a premium of about 74 percent to the stock's closing price on Thursday, they said. Reuters had reported on Thursday that Ignyta was in advanced talks to sell itself, just three years after going public with a focus on precision drugs and diagnostics.
Ir a respuesta
Moneyintruder 22/12/17 06:30
Ha respondido al tema Chicharros USA - bolsa internacional
LJPC Aquí noticia día 21 diciembre Sube un 14% en el Pre. FDA Approves La Jolla Pharmaceutical's (LJPC) Giapreza for Dangerously Low Blood Pressure December 21, 2017 6:00 PM The U.S. Food and Drug Administration today approved La Jolla Pharmaceutical's (NASDAQ: LJPC) Giapreza (angiotensin II) injection for intravenous infusion to increase blood pressure in adults with septic or other distributive shock. "Shock, the inability to maintain blood flow to vital tissues, can result in organ failure and death," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA’s Center for Drug Evaluation and Research. "There is a need for treatment options for critically ill hypotensive patients who do not adequately respond to available therapies." Blood pressure is the force of blood pushing against the walls of the arteries as the heart pumps out blood. Hypotension is abnormally low blood pressure. Shock is a critical condition in which blood pressure drops so low that the brain, kidneys and other vital organs can't receive enough blood flow to function properly. In a clinical trial of 321 patients with shock and a critically low blood pressure, significantly more patients responded to treatment with Giapreza compared to those treated with placebo. Giapreza effectively increased blood pressure when added to conventional treatments used to raise blood pressure. Giapreza can cause dangerous blood clots with serious consequences (clots in arteries and veins, including deep venous thrombosis); prophylactic treatment for blood clots should be used. This application received a Priority Review, under which the FDA’s goal is to take action on an application within six months when the agency determines that the drug, if approved, would significantly improve the safety or effectiveness of treating, diagnosing or preventing a serious condition. The FDA granted the approval of Giapreza to La Jolla Pharmaceutical Company. The FDA, an agency within the U.S. Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco
Ir a respuesta
Moneyintruder 13/12/17 09:07
Ha respondido al tema Chicharros USA - bolsa internacional
CHFS Tb +14% en premarket ( ayer bajaron un 6%) Noticia del 13 dic. CHF Solutions Signs International Distribution and Services Agreement with Singapore-based TRANSMEDIC Pte Ltd. December 13, 2017 08:00 ET | Source: CHF Solutions, Inc. EDEN PRAIRIE, Minn., Dec. 13, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today that it has entered into an international distribution agreement with Singapore-based TRANSMEDIC Pte Ltd to market and support CHF Solutions’ Aquadex FlexFlow® System in the region. “We are very pleased to expand our market reach into Singapore with our new distributor partner, TRANSMEDIC Pte Ltd, a premier medical technology sales and distribution company serving hospitals, clinics and health-centers in Southeast Asia,” said John Erb, CEO of CHF Solutions. “TRANSMEDIC has the market reach and service breadth to meet our expansion goals as we continue to execute our US and international growth plans. We have been in contact with healthcare providers that already own Aquadex FlexFlow consoles, and we look forward to TRANSMEDIC being able to service those units, bring them back into use and expanding the usage in the area,” Mr. Erb concluded. About TRANSMEDIC Pte Ltd. Formed in 1980, TRANSMEDIC offers direct sales, education and training plus technical support and maintenance for numerous medical technology, supplying hospitals, clinics and health-centers with a range of high quality products from 40 different companies, incorporating the latest technological advances. From its head office in Singapore and 7 offices allover Southeast Asia, this organization of 400 people provide full coverage of the SouthEast region. TRANSMEDIC is committed to provide the medical profession with a range of quality products incorporating the latest technology and backed by the highest level of customer service and support. About CHF Solutions CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since ...
Ir a respuesta